Novel platform of targeted multifunctional immunomodulatory antibody

Y-Trap is a biotechnology startup based in South San Francisco, focused on developing innovative fusion proteins aimed at enhancing cancer immunotherapy. Founded by scientists from prestigious institutions such as Johns Hopkins and Stanford, the company is addressing a critical gap in current immunotherapy approaches. While traditional therapies primarily work by activating T cells through immune checkpoint blockade, they often fail to rectify the immunosuppressive and tumor-promoting characteristics of immune cells prevalent within tumors. Y-Trap's unique approach involves the creation of antibody-ligand traps, referred to as "Y-traps," which are engineered to specifically counteract these detrimental immune cell phenotypes.

The company leverages a versatile computational engineering platform to design and optimize its Y-traps, which are intended to improve the efficacy of cancer treatments by modifying the tumor microenvironment. Y-Trap is actively advancing its lead programs towards first-in-human clinical studies, indicating a commitment to translating its innovative technologies into practical therapeutic solutions for cancer patients. Through its collaboration with Merck KGaA, Y-Trap aims to further enhance its research and development efforts in the field of immuno-oncology.

United States

Y-Trap, Inc., is a biotechnology company focused on the development of revolutionary technologies for cancer immunotherapy. The company's patented technology is a novel platform of targeted multifunctional immunomodulatory antibody-ligand traps for cancer immunotherapy. The ability of this novel class of next-generation multifunctional antibody-ligand traps to unleash potent antitumor immune responses offers a promising targeted immunotherapeutic strategy for many types of advanced and treatment-refractory cancers that evade current monoclonal antibodies and immune checkpoint inhibitors.

Y-Trap

Company Details